Mefruside
![]() | |
Systematic (IUPAC) name | |
---|---|
4-chloro-N1-methyl-N1-[(2-methyltetrahydrofuran-2-yl)methyl]benzene-1,3-disulfonamide | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
Legal status |
|
Identifiers | |
CAS Number |
7195-27-9 ![]() |
ATC code | C03BA05 (WHO) |
PubChem | CID 4047 |
ChemSpider |
3907 ![]() |
UNII |
X1NS9SNS92 ![]() |
KEGG |
D01877 ![]() |
Chemical data | |
Formula | C13H19ClN2O5S2 |
Molar mass | 382.88 g/mol |
| |
| |
![]() ![]() |
Mefruside (INN) is a diuretic indicated for the treatment of edema and hypertension.[1]
It was developed by Bayer A.G. and is sold under the tradename Baycaron.
References
- ↑ Allen HB, Lee DA (1973). "A general practice assessment of mefruside ('Baycaron') in the treatment of oedema and hypertension". Curr Med Res Opin 1 (9): 547–53. doi:10.1185/03007997309111720. PMID 4779251.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.